Kaynakça

  1. Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: A target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 2001;92:1-20.
  2. Khoury J, Langleben D. Heparin-like molecules inhibit pulmonary vascular pericyte proliferation in vitro. J Neurophysiology 2000;279:252-61.
  3. Perreault T, Berkenbosch JW, Barrington KJ, Decker ER, Wu C, Brock TA, et al. J. TBC3711, an ET(A) receptor antagonist, reduces neonatal hypoxia-induced pulmonary hypertension in piglets. Pediatr Res 2001;50:374-83.
  4. Rabinovitch M. Pathobiology of pulmonary hypertension. Clinics Chest Med 2001; 22:433-49.
  5. Yamashita Y, Nakagomi K, Takeda T, Hasegawa S, Mitsui Y. Effect of heparin on pulmonary fibroblasts and vascular cells. Thorax 1992;47:634-9.
  6. Fratacci MD, Frostell CG, Chen TY, Wain JC Jr, Robinson DR, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep. Anesthesiology 1991;75:990-9.
  7. Dickey LA, Butler TJ, Bergmann TM, Bates ME, Null DM. Selective heparinization of the extracorporeal membrane oxygenation circuit using continuous infusions of protamine and heparin in short-term pig model. Perfusion 1994;9:327-33.

Telif hakkı ve lisans

Telif hakkı © 2016 Yazar(lar). Açık erişimli bu makale, orijinal çalışmaya uygun şekilde atıfta bulunulması koşuluyla, herhangi bir ortamda veya formatta sınırsız kullanım, dağıtım ve çoğaltmaya izin veren Creative Commons Atıf Lisansı (CC BY) altında dağıtılmıştır.

Nasıl atıf yapılır

1.
Bayrakçı B. Pulmoner Vasküler Yeniden Biçimlenme Üzerine Heparin Etkisi. Turk J Pediatr Dis. 2016;10(4):297-298. https://doi.org/10.12956/tjpd.2016.261